Seres Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Mailing Address
200 SIDNEY STREET, CAMBRIDGE, MA, 02139
Phone
617 945 9626
Fiscal Year End
1231
EIN
274326290
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 3 Initial insider ownership report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
Annual Reports
10-K
March 12, 2026
- FDA-approved product Vowst offers a first-mover advantage in recurrent C. difficile infection.
- Advancing lead investigational candidate SER-155 for immunocompromised patients.
Material Events
8-K
Financial Distress
March 12, 2026
High Impact
- Achieved $5.7 million net income from continuing operations in 2025, a significant turnaround from a $125.8 million net loss in 2024.
- Strategic focus on promising inflammatory and immunology programs: SER-603 (IBD) and SER-155 (irEC).
Insider Trading
SELL
4 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.